Antibe Therapeutics closes previously announced non-brokered private placement

Antibe Therapeutics Inc. ("Antibe" or the "Corporation") (TSXV:ATE) has closed its previously announced non-brokered private placement raising gross proceeds of $3,015,398 (the "Offering") on the sale of 5,025,664 Common Shares of the Corporation.

Net proceeds from the Offering will be used for product development and for general corporate purposes.

In connection with the private placement, Antibe has agreed to pay finder's fees in the amount of $296,740 in cash and 494,565 Common Share purchase warrants ("Finder's Warrants"), each of which will entitle the holder to purchase a Common Share at a price of $0.60 per share until March 31, 2016.

The securities issued are subject to a four-month statutory hold period until August 1, 2014.

Antibe may complete a further closing up to the maximum offering amount announced in its March 28, 2014 press release, on or about April 4, 2014, subject to TSXV approval, as well as to the satisfaction of customary closing conditions.